Contrasting of BioDelivery Sciences International Inc. (BDSI) and PolarityTE Inc. (NASDAQ:PTE)

This is therefore a comparing of the institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations in BioDelivery Sciences International Inc. (NASDAQ:BDSI) and PolarityTE Inc. (NASDAQ:PTE). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioDelivery Sciences International Inc. 5 5.28 N/A -0.61 0.00
PolarityTE Inc. 8 18.22 N/A -3.96 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
BioDelivery Sciences International Inc. 0.00% -118.3% -34.9%
PolarityTE Inc. 0.00% 0% 0%

Volatility and Risk

BioDelivery Sciences International Inc. is 54.00% less volatile than S&P 500 because the company has a beta of 0.46. From a competition point of view, PolarityTE Inc. has a 1.14 beta which is 14.00% more volatile compared to S&P 500.

Liquidity

The current Quick Ratio of BioDelivery Sciences International Inc. is 2.6 while its Current Ratio is 2.9. Meanwhile, PolarityTE Inc. has a Current Ratio of 5.6 while its Quick Ratio is 5.6. PolarityTE Inc. is better positioned to pay off its short-term and long-term debts than BioDelivery Sciences International Inc.

Analyst Recommendations

The Recommendations and Ratings for BioDelivery Sciences International Inc. and PolarityTE Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
BioDelivery Sciences International Inc. 0 0 5 3.00
PolarityTE Inc. 0 0 0 0.00

The upside potential is 53.85% for BioDelivery Sciences International Inc. with consensus target price of $7.4.

Insider & Institutional Ownership

Roughly 60.9% of BioDelivery Sciences International Inc. shares are held by institutional investors while 45.6% of PolarityTE Inc. are owned by institutional investors. About 3.3% of BioDelivery Sciences International Inc.’s share are held by insiders. Competitively, insiders own roughly 33% of PolarityTE Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
BioDelivery Sciences International Inc. -5.36% -20.73% -21.4% -17.56% 40% 0.27%
PolarityTE Inc. 8.43% -15% -47.58% -72.95% -77.66% -64.71%

For the past year BioDelivery Sciences International Inc. has 0.27% stronger performance while PolarityTE Inc. has -64.71% weaker performance.

Summary

On 5 of the 8 factors PolarityTE Inc. beats BioDelivery Sciences International Inc.

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain. The company also develops Buprenorphine Depot Injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. It has a licensing and development agreement with Endo Pharmaceuticals, Inc.; Evonik Corporation; Collegium Pharmaceutical, Inc.; and Meda AB. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.

PolarityTE, Inc. operates as a biotechnology and regenerative biomaterials company in the United States. The company focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.